{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:14:44Z","timestamp":1794672884960,"version":"4.9.1"},"reference-count":144,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.amjopharm.2009.12.004","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T10:11:53Z","timestamp":1264500713000},"page":"293-323","source":"Crossref","is-referenced-by-count":39,"title":["Review of osteoporosis pharmacotherapy for geriatric patients"],"prefix":"10.1016","volume":"7","author":[{"given":"Brian J.","family":"Gates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis E.","family":"Sonnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina A.K.","family":"DuVall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"Dobbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2009.12.004_bib2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00013614-200501000-00003","article-title":"Estimating the opportunity costs of osteoporosis in the United States","volume":"21","author":"Vanness","year":"2005","journal-title":"Topics Geriatr Rehab."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00198-007-0403-3","article-title":"Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib5","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00198-007-0429-6","article-title":"Excess mortality following hip fracture: The role of underlying health status","volume":"18","author":"Tosteson","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00198-003-1463-7","article-title":"The risk and burden of vertebral fractures in Sweden","volume":"15","author":"Kanis","year":"2004","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1359\/jbmr.1997.12.1.24","article-title":"Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation","volume":"12","author":"Ray","year":"1997","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","article-title":"Excess mortality after hospitalisation for vertebral fracture","volume":"15","author":"Kanis","year":"2004","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s001980050067","article-title":"Mortality associated with vertebral deformity in men and women: Results from the European Prospective Osteoporosis Study (EPOS)","volume":"8","author":"Ismail","year":"1998","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: An observational study","volume":"353","author":"Center","year":"1999","journal-title":"Lancet."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00198-003-1412-5","article-title":"Incident vertebral fractures and mortality in older women: A prospective study","volume":"14","author":"Kado","year":"2003","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","article-title":"A meta-analysis of previous fracture and subsequent fracture risk","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib13","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s001980200084","article-title":"Does a fracture at one site predict later fractures at other sites? A British cohort study","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/er.21.2.115","article-title":"Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0889-8529(02)00078-6","article-title":"The structural and biomechanical basis of the gain and loss of bone strength in women and men","volume":"32","author":"Seeman","year":"2003","journal-title":"Endocrinol Metab Clin North Am."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib16","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1152\/japplphysiol.00564.2003","article-title":"Invited review: Pathogenesis of osteoporosis","volume":"95","author":"Seeman","year":"2003","journal-title":"J Appl Physiol."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S8756-3282(97)00100-2","article-title":"Modeling the mechanical behavior of vertebral trabecular bone: Effects of age-related changes in microstructure","volume":"21","author":"Silva","year":"1997","journal-title":"Bone."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib19","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib20","unstructured":"Nuti R, Brandi ML, Isaia G, et al. New perspectives on the definition and the management of severe osteoporosis: The patient with two or more fragility fractures[published online ahead of print July 17, 2009]. J Endocrinol Invest."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.4065\/81.5.662","article-title":"Diagnosis, screening, prevention, and treatment of osteoporosis","volume":"81","author":"Mauck","year":"2006","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s001980170031","article-title":"Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: A systematic review of the literature","volume":"12","author":"Espallargues","year":"2001","journal-title":"Osteoporos Int."},{"issue":"Suppl 2","key":"10.1016\/j.amjopharm.2009.12.004_bib23","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.yebeh.2003.11.028","article-title":"Treatment of anticonvulsant drug-induced bone disease","volume":"5","author":"Drezner","year":"2004","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib25","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/archneur.58.9.1369","article-title":"Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy","volume":"58","author":"Valmadrid","year":"2001","journal-title":"Arch Neurol."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00023210-200115080-00006","article-title":"Adverse effects of antiepileptic drugs on bone structure: Epidemiology, mechanisms and therapeutic implications","volume":"15","author":"Pack","year":"2001","journal-title":"CNS Drugs."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1053\/seiz.1999.0301","article-title":"Bone density and antiepileptic drugs: A case-controlled study","volume":"8","author":"Stephen","year":"1999","journal-title":"Seizure."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib28","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1212\/WNL.58.9.1348","article-title":"Effect of antiepileptic drugs on bone density in ambulatory patients","volume":"58","author":"Farhat","year":"2002","journal-title":"Neurology."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib31","doi-asserted-by":"crossref","first-page":"680","DOI":"10.7326\/0003-4819-148-9-200805060-00008","article-title":"Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians [published correction appears in Ann Intern Med. 2008;148:888]","volume":"148","author":"Qaseem","year":"2008","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.286.1.57","article-title":"Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry","volume":"286","author":"Cadarette","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.gerinurse.2008.07.003","article-title":"Identifying women with low bone mass: A systematic review of screening tools","volume":"30","author":"McLeod","year":"2009","journal-title":"Geriatr Nurs."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib34","first-page":"37","article-title":"Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density","volume":"4","author":"Lydick","year":"1998","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib35","first-page":"1289","article-title":"Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry","volume":"162","author":"Cadarette","year":"2000","journal-title":"CMAJ."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1067\/mob.2000.106594","article-title":"Identification of at-risk women for osteoporosis screening","volume":"183","author":"Weinstein","year":"2000","journal-title":"Am J Obstet Gynecol."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s001980170070","article-title":"A simple tool to identify Asian women at increased risk of osteoporosis","volume":"12","author":"Koh","year":"2001","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-137-6-200209170-00015","article-title":"Screening for postmenopausal osteoporosis: A review of the evidence for the US Preventive Services Task Force","volume":"137","author":"Nelson","year":"2002","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib41","series-title":"Dietary Reference Intakes: For Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride","year":"1997"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib42","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0899-9007(97)83011-0","article-title":"Calcium and osteoporosis","volume":"13","author":"Nordin","year":"1997","journal-title":"Nutrition."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/07315724.1990.10720413","article-title":"Superior calcium absorption from calcium citrate than calcium carbonate using external forearm counting","volume":"9","author":"Harvey","year":"1990","journal-title":"J Am Coll Nutr."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s001980050111","article-title":"Absorption of calcium as the carbonate and citrate salts, with some observations on method","volume":"9","author":"Heaney","year":"1999","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jn\/86.2.125","article-title":"Effect of high phosphorus intake on calcium and phosphorus metabolism in man","volume":"86","author":"Spencer","year":"1965","journal-title":"J Nutr."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib46","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM198904273201703","article-title":"Effect of the time of administration of calcium acetate on phosphorus binding","volume":"320","author":"Schiller","year":"1989","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib47","first-page":"317","article-title":"Calcium and iron absorption: Mechanism of action and nutritional importance","volume":"46","author":"Hallberg","year":"1992","journal-title":"Eur J Clin Nutr."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib48","first-page":"11","article-title":"The effect of a high intake of calcium on magnesium metabolism in normal subjects and patients with chronic renal failure","volume":"32","author":"Clarkson","year":"1967","journal-title":"Clin Sci."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa055218","article-title":"Calcium plus vitamin D supplementation and the risk of fractures [published correction appears in N Engl J Med. 2006;354:1102]","volume":"354","author":"Jackson","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib50","series-title":"Health Professional's Drug Guide","author":"Shannon","year":"2000"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib51","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI115317","article-title":"Intestinal absorption of magnesium from food and supplements","volume":"88","author":"Fine","year":"1991","journal-title":"J Clin Invest."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib52","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/ajcn\/69.5.842","article-title":"Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety","volume":"69","author":"Vieth","year":"1999","journal-title":"Am J Clin Nutr."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-0-387-77574-6_5","article-title":"Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes","volume":"624","author":"Bischoff-Ferrari","year":"2008","journal-title":"Adv Exp Med Biol."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib54","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","article-title":"Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials","volume":"293","author":"Bischoff-Ferrari","year":"2005","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib55","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.291.16.1999","article-title":"Effect of vitamin D on falls: A meta-analysis","volume":"291","author":"Bischoff-Ferrari","year":"2004","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib56","series-title":"Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride","year":"1997"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib57","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/SMJ.0b013e3181a8d1e4","article-title":"The lack of vitamin D toxicity with megadose of daily ergocalciferol (D2) therapy. A case report and literature review","volume":"102","author":"Stephenson","year":"2009","journal-title":"South Med J."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib58","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/07315724.1994.10718447","article-title":"The role of vitamin D in toxic metal absorption: A review","volume":"13","author":"Moon","year":"1994","journal-title":"J Am Coll Nutr."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib59","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1532-5415.2000.tb06884.x","article-title":"Physical activity, falls, and fractures among older adults: A review of the epidemiologic evidence","volume":"48","author":"Gregg","year":"2000","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib60","first-page":"CD000333","article-title":"Exercise for preventing and treating osteoporosis in postmenopausal women","volume":"3","author":"Bonaiuti","year":"2002","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib61","first-page":"CD007146","article-title":"Interventions for preventing falls in older people living in the community","volume":"2","author":"Gillespie","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1359\/jbmr.1999.14.2.215","article-title":"Smoking increases bone loss and decreases intestinal calcium absorption","volume":"14","author":"Krall","year":"1999","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib64","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3945\/ajcn.2008.26765","article-title":"Effects of beer, wine, and liquor intakes on bone mineral density in older men and women","volume":"89","author":"Tucker","year":"2009","journal-title":"Am J Clin Nutr."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ajcn\/79.1.155","article-title":"Nutritional associations with bone loss during the menopausal transition: Evidence of a beneficial effect of calcium, alcohol, and fruit and vegetable nutrients and of a detrimental effect of fatty acids","volume":"79","author":"Macdonald","year":"2004","journal-title":"Am J Clin Nutr."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib66","series-title":"Calcium and Phosphorus in Health and Disease","article-title":"Effects of alcohol on calcium homeostasis and bone","author":"Hirsch","year":"1996"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib67","year":"1994","journal-title":"Results from the United States Department of Agriculture's 1994\u201396 Continuing Survey of Food Intakes by Individuals\/Diet and Health Knowledge Survey"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib68","first-page":"102","article-title":"Osteoporosis and alcohol intake [in Japanese]","volume":"15","author":"Kogawa","year":"2005","journal-title":"Clin Calcium."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib69","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: From bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib70","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib71","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF02196199","article-title":"The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats","volume":"6","author":"Russell","year":"1970","journal-title":"Calcif Tissue Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structureactivity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib73","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanaugh","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib75","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib76","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib77","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib78","first-page":"46","article-title":"The effect of alendronate therapy on osteoporosis fracture in the vertebral fracture arm of the Fracture Intervention Trial","volume":"101","author":"Black","year":"1999","journal-title":"Int J Clin Pract. Suppl."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib79","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib80","doi-asserted-by":"crossref","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonver-tebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib81","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib82","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib83","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","article-title":"Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old","volume":"52","author":"Boonen","year":"2004","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib84","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib85","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib86","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib87","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial [published correction appears in JAMA. 1999;282:2124]","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib88","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1359\/jbmr.070904","article-title":"Effects of raloxifene on fracture risk in postmenopausal women: The Raloxifene Use for the Heart Trial","volume":"23","author":"Ensrud","year":"2008","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib89","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fracture study","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib90","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib91","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib92","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1532-5415.2006.00696.x","article-title":"Between-meal risedronate does not alter bone turnover in nursing home residents","volume":"54","author":"Agrawal","year":"2006","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib93","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib94","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clinthera.2009.02.012","article-title":"Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study","volume":"31","author":"Ste-Marie","year":"2009","journal-title":"Clin Ther."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib95","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-Year results from the DIVA study","volume":"35","author":"Eisman","year":"2008","journal-title":"J Rheumatol."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib96","series-title":"Reclast (zoledronic acid) [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib97","series-title":"Fosamax (alendronate) [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib98","series-title":"Actonel (risedronate sodium) [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib99","series-title":"Boniva (ibandronate sodium) [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/SMJ.0b013e31816127d9","article-title":"Osteonecrosis of the jaw","volume":"101","author":"Watts","year":"2008","journal-title":"South Med J."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib101_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib101_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib102","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib103","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib104","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonateassociated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib105","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw\u2014do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib106","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006;145:235]","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib107","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonateinduced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib108","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.14219\/jada.archive.2006.0355","article-title":"Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations","volume":"137","year":"2006","journal-title":"J Am Dent Assoc."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib109","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMc076132","article-title":"Alendronate and atrial fibrillation","volume":"356","author":"Cummings","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib110","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archinte.168.8.826","article-title":"Use of alendronate and risk of incident atrial fibrillation in women","volume":"168","author":"Heckbert","year":"2008","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib111","first-page":"1980","article-title":"The estrogen receptor: A model for molecular medicine","volume":"9","author":"Jensen","year":"2003","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib112","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1126\/science.273.5279.1222","article-title":"Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene [published correction appears in Science. 1997;275:1249]","volume":"273","author":"Yang","year":"1996","journal-title":"Science."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib113","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","article-title":"Severity of prevalent fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the MORE trial","volume":"33","author":"Delmas","year":"2003","journal-title":"Bone."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib114","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators\u2014mechanisms of action and application to clinical practice [published correction appears in N Engl J Med. 2003;348:1192]","volume":"348","author":"Riggs","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib115","series-title":"Evista (raloxifene hydrochloride) [prescribing information]","year":"2008"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib116","first-page":"137","article-title":"Calcitonin: A drug of the past or future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality","volume":"22","author":"Karsdal","year":"2008","journal-title":"Bio Drugs."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib117","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1359\/JBMR.050411","article-title":"Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: Results from the QUEST study","volume":"20","author":"Chesnut","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib118","series-title":"Miacalcin (calcitonin-salmon) [package insert]","year":"2002"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib119","series-title":"Forteo (teriparatide) [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib120","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1532-5415.2006.00695.x","article-title":"Safety and efficacy of teriparatide in elderly women with established osteoporosis: Bone anabolic therapy from a geriatric perspective","volume":"54","author":"Boonen","year":"2006","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib121","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1185\/03007990802466595","article-title":"Bone density after teriparatide in patients with or without prior antiresorptive treatment: One-year results from the EUROFORS study","volume":"24","author":"Minne","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib122","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib123","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11914-008-0003-y","article-title":"Safety of parathyroid hormone for the treatment of osteoporosis","volume":"6","author":"Miller","year":"2008","journal-title":"Curr Osteoporos Rep."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib124","series-title":"Premarin (conjugated estrogens) [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2009.12.004_bib125","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib126","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/0003-4819-148-9-200805060-00003","article-title":"Relative effectiveness of osteoporosis drugs for preventing non-vertebral fracture","volume":"148","author":"Cadarette","year":"2008","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00198-006-0274-z","article-title":"Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study","volume":"18","author":"Silverman","year":"2007","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk","volume":"7","author":"Watts","year":"2004","journal-title":"J Clin Densitom."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib129","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2008.10.052","article-title":"Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis","volume":"44","author":"Sebba","year":"2009","journal-title":"Bone."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib130","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.87.4.1586","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib131","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2796.2004.01317.x","article-title":"Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: Results of EFFECT (Efficacy of Fosamax versus Evista Comparison Trial) international","volume":"255","author":"Sambrook","year":"2004","journal-title":"J Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib132","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized doubleblind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib133","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.clinthera.2009.04.018","article-title":"Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the Monthly Oral Therapy With Ibandronate for Osteoporosis Intervention (MOTION) study","volume":"31","author":"Emkey","year":"2009","journal-title":"Clin Ther."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib134_1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/01.gme.0000222475.93345.b3","article-title":"Management of osteoporosis in postmenopausal women: 2006 Position statement of The North American Menopause Society","volume":"13","year":"2006","journal-title":"Menopause."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib134_2","first-page":"368","article-title":"Management of osteoporosis in postmenopausal women: 2006 Position statement of The North American Menopause Society","volume":"13","year":"2006","journal-title":"Menopause."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib135","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: Differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib136","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib137","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib138","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/archinte.166.11.1209","article-title":"The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis","volume":"166","author":"Liu","year":"2006","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib139","first-page":"605","article-title":"Therapies for treatment of osteoporosis in US women: Cost-effectiveness and budget impact considerations","volume":"14","author":"Tosteson","year":"2008","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib140","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00019053-200725110-00003","article-title":"The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: A structured review of the literature","volume":"25","author":"Fleurence","year":"2007","journal-title":"Pharmaco Economics."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib141","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","article-title":"Cost-effective osteoporosis treatment thresholds: The United States perspective","volume":"19","author":"Tosteson","year":"2008","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib142","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2217\/14622416.9.6.733","article-title":"Pharmacogenetics of bone treatments: The VDR and ERalpha gene story","volume":"9","author":"Massart","year":"2008","journal-title":"Pharmacogenomics."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib143","doi-asserted-by":"crossref","first-page":"655","DOI":"10.5414\/CPP44655","article-title":"Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females","volume":"44","author":"Pillai","year":"2006","journal-title":"Int J Clin Pharmacol Ther."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib144","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s001980050171","article-title":"Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women","volume":"9","author":"Wasnich","year":"1999","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11926-009-0025-1","article-title":"Advances in renal bone disease: Osteoporosis and chronic kidney disease","volume":"11","author":"Barnato","year":"2009","journal-title":"Curr Rheumatol Rep."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib146","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger","year":"1998","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9220","article-title":"A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis","volume":"9","author":"Stevenson","year":"2005","journal-title":"Health Technol Assess."},{"key":"10.1016\/j.amjopharm.2009.12.004_bib148","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-149-6-200809160-00007","article-title":"Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American College of Physicians","volume":"149","author":"Qaseem","year":"2008","journal-title":"Ann Intern Med."}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594609000890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594609000890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T23:48:39Z","timestamp":1739749719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594609000890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":144,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S1543594609000890"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2009.12.004","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}